• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab.

作者信息

Sukumar Senthil, George James N, Cataland Spero R

机构信息

Division of Hematology, Department of Medicine, The Ohio State University College of Medicine, Columbus, Ohio.

Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

出版信息

Am J Hematol. 2020 Apr;95(4):E76-E77. doi: 10.1002/ajh.25715. Epub 2020 Jan 14.

DOI:10.1002/ajh.25715
PMID:31894592
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9292479/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9c/9292479/2b38e1d647f6/AJH-95-E76-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9c/9292479/2b38e1d647f6/AJH-95-E76-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9c/9292479/2b38e1d647f6/AJH-95-E76-g001.jpg

相似文献

1
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab.共同决策、血栓性血小板减少性紫癜与卡泊单抗
Am J Hematol. 2020 Apr;95(4):E76-E77. doi: 10.1002/ajh.25715. Epub 2020 Jan 14.
2
Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI).成功治疗三例自身免疫性血栓性血小板减少性紫癜患者，治疗方案为：卡普昔单抗、皮质类固醇、血浆置换、利妥昔单抗和静脉注射免疫球蛋白（CASPERI）。
Transfus Apher Sci. 2021 Feb;60(1):103011. doi: 10.1016/j.transci.2020.103011. Epub 2020 Nov 7.
3
A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.卡普拉珠单抗治疗获得性血栓性血小板减少性紫癜的评价。
Expert Rev Hematol. 2020 Nov;13(11):1153-1164. doi: 10.1080/17474086.2020.1819230. Epub 2020 Oct 12.
4
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.卡普拉珠单抗治疗获得性血栓性血小板减少性紫癜。
N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.
5
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.卡普雷珠单抗治疗获得性血栓性血小板减少性紫癜。
N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533.
6
Caplacizumab for relapsing thrombotic thrombocytopenic purpura.卡普兰珠单抗治疗复发型血栓性血小板减少性紫癜。
Pediatr Nephrol. 2019 Sep;34(9):1625-1628. doi: 10.1007/s00467-019-04281-z. Epub 2019 Jun 8.
7
Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.卡普芦单抗：一种抗血管性血友病因子抗体，用于治疗血栓性血小板减少性紫癜。
Am J Health Syst Pharm. 2020 Jul 23;77(15):1201-1207. doi: 10.1093/ajhp/zxaa151.
8
Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.卡泊单抗治疗免疫介导的血栓性血小板减少性紫癜。
Drugs Today (Barc). 2019 Jun;55(6):367-376. doi: 10.1358/dot.2019.55.6.2989843.
9
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.卡普雷珠单抗可降低获得性血栓性血小板减少性紫癜患者的主要血栓栓塞事件、恶化事件和死亡的发生频率。
J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5.
10
Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura.卡普拉珠单抗在获得性血栓性血小板减少性紫癜治疗中的作用。
J Oncol Pharm Pract. 2020 Oct;26(7):1695-1702. doi: 10.1177/1078155220934862. Epub 2020 Jun 30.

引用本文的文献

1
Challenges in managing iTTP: insights into ADAMTS13 inhibitor boosting during caplacizumab therapy.治疗免疫性血小板减少性紫癜的挑战：卡泊单抗治疗期间提高ADAMTS13活性的见解
Ann Hematol. 2025 Mar;104(3):1507-1514. doi: 10.1007/s00277-025-06318-w. Epub 2025 Mar 19.
2
Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.卡普拉珠单抗与免疫性血栓性血小板减少性紫癜标准治疗的真实世界疗效比较。
Blood Adv. 2022 Dec 27;6(24):6219-6227. doi: 10.1182/bloodadvances.2022008028.
3
Therapeutic apheresis in kidney diseases: an updated review.

本文引用的文献

1
Realizing Shared Decision-making in Practice.在实践中实现共同决策
JAMA. 2019 Sep 3;322(9):811-812. doi: 10.1001/jama.2019.9797.
2
Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura.不进行血浆置换的卡泊单抗治疗获得性血栓性血小板减少性紫癜。
N Engl J Med. 2019 Jul 4;381(1):92-94. doi: 10.1056/NEJMc1905426.
3
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.卡普拉珠单抗治疗获得性血栓性血小板减少性紫癜。
肾脏病的治疗性血液净化：更新综述。
Ren Fail. 2022 Dec;44(1):842-857. doi: 10.1080/0886022X.2022.2073892.
4
Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.一名耶和华见证会信徒患免疫介导的血栓性血小板减少性紫癜——联合体外免疫吸附、卡泊单抗、类固醇和利妥昔单抗的疗效
Clin Case Rep. 2022 May 20;10(5):e05902. doi: 10.1002/ccr3.5902. eCollection 2022 May.
5
SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura.严重急性呼吸综合征冠状病毒2型疫苗接种与免疫性血栓性血小板减少性紫癜
Blood. 2022 Apr 21;139(16):2570-2573. doi: 10.1182/blood.2022015545.
6
Clinical relapse of immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination.新型冠状病毒肺炎疫苗接种后免疫介导的血栓性血小板减少性紫癜的临床复发
Res Pract Thromb Haemost. 2022 Feb 7;6(1):e12658. doi: 10.1002/rth2.12658. eCollection 2022 Jan.
7
Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist.妊娠相关性严重血小板减少症伴微血管病性溶血性贫血：血液科会诊医师指南
Am J Hematol. 2021 Dec 1;96(12):1655-1665. doi: 10.1002/ajh.26328. Epub 2021 Sep 4.
8
Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management.血栓性血小板减少性紫癜：病理生理学、诊断与管理
J Clin Med. 2021 Feb 2;10(3):536. doi: 10.3390/jcm10030536.
9
Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab.在卡普拉珠单抗治疗下，选择特定患者无需进行血浆置换治疗获得性血栓性血小板减少性紫癜。
J Thromb Haemost. 2020 Nov;18(11):3061-3066. doi: 10.1111/jth.15045. Epub 2020 Sep 6.
10
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.ADAMTS13 和 VWF 活性指导 aTTP 患者个体化的卡普拉珠单抗治疗。
Blood Adv. 2020 Jul 14;4(13):3093-3101. doi: 10.1182/bloodadvances.2020001987.
N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.
4
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.血栓性血小板减少性紫癜：1995年至2015年的诊断标准、临床特征及长期预后
Blood Adv. 2017 Apr 6;1(10):590-600. doi: 10.1182/bloodadvances.2017005124. eCollection 2017 Apr 11.
5
Shared decision making--pinnacle of patient-centered care.共同决策——以患者为中心的医疗的巅峰。
N Engl J Med. 2012 Mar 1;366(9):780-1. doi: 10.1056/NEJMp1109283.